CliffBio
small molecule

GANZYK-RTU

GANCICLOVIR

Loss of exclusivitySeptember 2034latest FDA-listed patent expiry
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameGANZYK-RTU
Active ingredientGANCICLOVIR
Strength500MG/250ML (2MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9486530September 2034product

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GANZYK-RTU patent cliff — loss of exclusivity September 2034 | CliffBio